

Benchmark Holdings

BMK  85.48p ▼ -2.0 -2.3%

Market Cap
Enterprise Value
Revenue
Position in UK Edition

£119.2m
£123.6m
£27.5m
883rd

Value 27
Quality 67
Momentum 39
StockRank™ 41



Momentum		
Relative Strength (%)		
1m	+1.8%	●
3m	-17.6%	●
1yr	-8.2%	●
Volume Change (%)		
10d v 3m	+459%	●
Price vs... (%)		
52w High	-40.0%	●
50d MA	-0.62%	●
200d MA	-16.6%	●




Growth & Value			vs. industry	vs. market
Trailing 12m				
PE Ratio (ttm)	28.2			
PEG Ratio (ttm)	n/a			
EPS Growth (ttm)	36.7 %			
Dividend Yield (ttm)	n/a %			
Valuation (ttm)				
Price to Book Value	10.0			
Price to Tang. Book	10.0			
Price to Free Cashflow	22.2			
Price to Sales	4.33			
EV to EBITDA	19.8			

Margin of Safety (beta)		
Relative to Sector	-12%	
Graham Formula	-23%	
Stability Value (EPV)	-76%	

Screens Passed		
BMK doesn't qualify for our  screens.		
Find out why: View Checklists		

Quality			vs. industry	vs. market
Return on Capital	35.8 %			
Return on Equity	43.3 %			
Operating Margin	18.5 %			


Financial Summary										
Year End 30th Sep		2008	2009	2010	2011	2012	2013	2014E	2015E	CAGR / Avg
Revenue	£m	0.000	0.000	0.000	12.9	18.5	27.5	29.9	42.1	+46.2%
Operating Profit	£m	0.000	0.000	0.000	2.56	3.64	5.10			+41.2%
Net Profit	£m	0.000	0.000	0.000	1.94	2.78	4.29	-3.30	1.80	+48.7%
EPS Reported	p	0.000	0.000	0.000	1.42	2.04	3.15			+48.7%
EPS Normalised	p	0.000	0.000	0.000	1.42	2.26	3.09		1.60	+47.3%
EPS Growth	%					+58.7	+36.7			
PE Ratio	x					28.2	n/a	54.4		
PEG	x					n/a	n/a	0.27		
Profitability										
Operating Margin	%				19.9	19.6	18.5			+19.3%
ROA	%				45.5	21.0	21.3			
ROCE	%				41.7	31.8	35.8			+36.4%
ROE	%				70.8	41.4	43.3			+51.8%
Cashflow										
Op. Cashflow ps	p	0.000	0.000	0.000	1.83	1.73	4.04			+48.5%
Capex ps	p	0.000	0.000	0.000	0.46	0.042	0.12			-49.7%
Free Cashflow ps	p	0.000	0.000	0.000	1.38	1.69	3.93			+68.6%
Dividends										
Dividend ps	p									
Dividend Growth	%									
Dividend Yield	%									
Dividend Cover	x									
Balance Sheet										
Cash etc	£m	0.000	0.000	0.000	1.81	1.02	3.25			+34.0%
Working Capital	£m	n/a	n/a	n/a	4.08	5.00	6.76			+28.7%
Net Fixed Assets	£m	0.000	0.000	0.000	1.21	2.40	3.81			+77.6%
Net Debt	£m	0.000	0.000	0.000	-1.37	3.54	1.19			
Book Value	£m	0.000	0.000	0.000	5.49	7.96	11.9			+47.2%
Average Shares	m	0.000	0.000	0.000	136.4	136.4	136.4			
Book Value ps	p	0.000	0.000	0.000	4.02	5.83	8.72			+47.2%



Other Ratios			
Leverage (ttm)		total	ex intang
Gross Gearing		%	
Net Gearing		%	
Cash / Assets		%	14.5
Liquidity (ttm)		Efficiency (ttm)	
Curr. Ratio	n/a	Asset Turnover	2.46
Quick Ratio	n/a	Rec's Turnover	5.19
Interest Cov.	20.3	Stock Turnover	3.05

Recent History			vs. industry	vs. market
Latest interim period (ended 30th Sep '13) vs. prior year				
Sales Growth	n/a	%		
EPS Growth	n/a	%		
3yr Compound Annual Growth Rate				
Sales Growth	n/a	%		
EPS Growth	n/a	%		
DPS Growth	n/a	%		

Graphical History Current Fiscal Year 2014




Broker Forecasts 30th Sep 2014 30th Sep 2015

--	--

Broker Consensus Trend [2 Brokers](#)



Price Target: N/A	Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a	(£)	(p)	(£)	(£)	(p)	(£)
Consensus Estimate	-3.30m	-	-	1.80m	1.60	-
1m Change	-	+1.00	-	-	+0.30	-
3m Change	-	+1.00	-	-	+0.30	-



Profile Summary

[Home Page](#) · [News Releases](#) · [Investor Relations](#) · [Financial Information](#) · [Corporate History/Profile](#) · [Executives](#) · [Products/Services](#)



Benchmark Holdings Plc is a United Kingdom-based company which is established international animal health, technical publishing and sustainability business. Its activities include the development, manufacture and commercialization of animal health vaccines, medicines, biocides and diagnostics with a key focus on aquaculture. The Company has three divisions: Animal Health; Technical Publishing; and Sustainability Science. Animal Health focus is on the use of applied biotechnology and the healthcare sciences in aquaculture. Sustainability Science is an international provider of research, advice and training. Technical Publishing has built an estimated global readership of six million across its publications and is starting to leverage this user base to grow its sales of specialist products and services into the agri-food sector. In February 2014, Benchmark Holdings PLC purchased aquaculture vaccine and development assets from animal health company Zoetis Inc.

Directors: [Malcolm Pye](#) (CEO) 56, [Mark Plampin](#) (CFO) 45, [Roland Bonney](#) (COO) 49, [James Banfield](#) (MDR), [Dave Cox](#) (MDR), [Paul Cook](#) (OTH), [Ruth Layton](#) (OTH), [Bob Long](#) (OTH), [John Marshall](#) (OTH), [Hernan Pizarro](#) (OTH), [Basil Brookes](#) (NID) 56, [Alex Hambro](#) (NID) 50, [Susan Searle](#) (NID) 50,

No. of Employees: 157

No. of Shareholders: 0

Last Annual September 30th, 2013
Last Interim January 1st, 1970
Shares in Issue 136,977,095
ISIN GB00BGHPT808

Sector [Healthcare](#)
Industry [Pharmaceuticals](#)
Index
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?



Address [Benchmark House 8 Smithy Wood Drive, SHEFFIELD, S35 1QN, United Kingdom](#)

Web <http://www.benchmarkplc.com>

Phone +44 114 2409939

Contact ()

Auditors BDO LLP


BMK Quote

BMK Share Price
 GBp
85.48p
 Traded 10:57am · Minimum 15 min delayed · NMS: 1.000k

Day's Change
-2.0 -2.3%

Volume 44,682	Bid - Ask 83.0 - 87.0	Low - High 0.0 - 0.0	Spread 468bps
Avg Vol (3m) 158,538	Open - Close 87.0 - 87.0	12m Range 83.0 - 83.0	Beta 0.00

BMK Share Price Performance



Latest BMK News Announcements (delayed)

[More »](#)

Mon 8:46am [Holding\(s\) in Company](#)
 16th May [Trading Update and Notice of Results](#)
 12th Mar [Directors shareholding](#)
 11th Mar [Result of AGM](#)
 17th Feb [Acquisition](#)
 14th Feb [Posting of Annual Report and Notice of AGM](#)

Upcoming BMK Events

No upcoming events.

Industry Peer Group	
	Hutchison China Me... Compare vs BMK
	SkyePharma Compare vs BMK
	Vectura Compare vs BMK
	Circassia Pharmace... Compare vs BMK
	Dechra Pharmaceuti... Compare vs BMK
	Abcam Compare vs BMK
	Ranbaxy Laboratori... Compare vs BMK
	BTG Compare vs BMK
Healthcare Pharmaceuticals	

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.